Across 45 European renal cell carcinoma phase 2 & 3 trials, CROs or CRO-like specialist vendors were listed in 25 trials, equal to 55.6%. PPD / Thermo Fisher was the most active named provider with 10 trial appearances, followed by ICON plc and Parexel with 8 each. CRO need was strongest in multi-country CTIS/EU submission programmes: 12 of 12 trials across 5 or more countries used CRO support.
Among the 25 CRO-supported trials, PPD / Thermo Fisher appeared in 10 trials, equal to 40.0% of CRO-supported trials and 22.2% of all 45 trials. ICON plc and Parexel each appeared in 8 trials, equal to 32.0% of CRO-supported trials.
The active CRO market is concentrated around large global delivery groups and platform specialists. PPD / Thermo Fisher, ICON plc, Parexel, Almac, Fortrea, and Medidata form the recurring vendor set most visible in European RCC CTIS submissions.
PPD / Thermo Fisher had the broadest cumulative footprint: 10 trials linked to 60 country activations, 248 sites, and 2,023 planned participants. ICON plc followed with 49 country activations, 179 sites, and 1,395 participants.
| CRO | Trials | Countries | Sites | Participants |
|---|---|---|---|---|
| PPD / Thermo Fisher | 10 | 60 | 248 | 2,023 |
| ICON plc | 8 | 49 | 179 | 1,395 |
| Parexel | 8 | 55 | 228 | 1,104 |
| Medidata Solutions | 5 | 43 | 216 | 980 |
| Almac Clinical Technologies | 7 | 48 | 168 | 746 |
| Fortrea | 5 | 26 | 108 | 326 |
The CROs most useful for RCC sponsors are not only the most frequent names; they are also the providers attached to broad CTIS country rollouts, high site counts, and large participant footprints.
CRO use was driven more by geographic and site complexity than by participant volume alone. CRO support appeared in 12 of 12 trials with 5 or more countries, compared with 13 of 16 trials with 2–4 countries and 0 of 17 single-country trials.
The practical CRO trigger in European RCC phase 2 & 3 trials is multi-country CTIS/EU execution. Once a study expands beyond a single country, CRO use rises sharply; when it reaches 5 or more countries, CRO involvement becomes universal in this cohort.
Disease breadth was a stronger CRO signal than RCC subtype alone. Trials covering 6 or more diseases used CROs in 7 of 8 cases, equal to 87.5%, while single-disease RCC trials used CROs in 11 of 17 cases, equal to 64.7%.
CRO demand is highest when RCC is embedded in broad solid-tumor or biomarker-defined programmes. These studies create more operational, eligibility, lab, and endpoint coordination pressure than narrow single-country RCC trials.
The most common outsourced function was central lab, biomarker, or bioanalysis work, appearing in 21 of 45 trials, equal to 46.7%. IRT/randomisation/eClinical systems appeared in 17 of 45 trials, and full-service clinical operations or project delivery appeared in 16 of 45 trials.
RCC outsourcing is not limited to classical monitoring. The strongest recurring demand is for biomarker/lab execution, eClinical infrastructure, imaging review, and CTIS/EU-facing regulatory or medical-information support.
France and Spain carried the largest country-level RCC phase 2 & 3 footprint. France appeared in 28 trial-country activations with 208 sites and 1,910 participants, while Spain appeared in 27 activations with 173 sites and 1,324 participants.
| Country | Trial-country activations | Sites | Participants | CRO-supported activations |
|---|---|---|---|---|
| France | 28 | 208 | 1,910 | 21 / 28 · 75.0% |
| Spain | 27 | 173 | 1,324 | 22 / 27 · 81.5% |
| Italy | 14 | 137 | 647 | 10 / 14 · 71.4% |
| Poland | 15 | 59 | 423 | 14 / 15 · 93.3% |
| Belgium | 10 | 29 | 311 | 10 / 10 · 100.0% |
| Germany | 11 | 58 | 272 | 11 / 11 · 100.0% |
France and Spain are the main operational load centres for European RCC trial delivery, while Belgium and Germany show universal CRO-supported country activations in this cohort.
The same CTIS-derived sponsor and geography fields answer whether CRO use differs by sponsor type and whether CRO-supported trials are attached to more complex EU submission patterns.
The CTIS timing pattern should be read as a complexity signal rather than a causal CRO effect. CROs are concentrated in broader, pharma-sponsored, multi-country RCC programmes where EU submission coordination, country activation, vendor management, and site execution are heavier.
CRO means contract research organization. CTIS means Clinical Trials Information System. IRT means interactive response technology for randomisation and treatment allocation. IMP means investigational medicinal product. eCOA, ePRO, and EDC refer to electronic clinical outcome assessment, electronic patient-reported outcome, and electronic data capture systems.